Lesson Plan

• Describe the principal advantages of recombinant human proteins for therapeutic use.
• Compare recombinant insulin, factor VIII, and adenosine deaminase in terms of production systems and safety benefits.
• Explain how recombinant technology enhances scalability and reduces immunogenicity.
• Evaluate the impact of these recombinant therapeutics on patient outcomes.

• Projector and screen for slide presentation
• Printed handout containing the comparative table of the three proteins
• Whiteboard and markers
• Diagram of recombinant protein production flow‑chart
• Clicker or online quiz platform for formative checks

Begin with a brief video clip showing a patient injecting insulin, prompting discussion about how these medicines are made. Ask students what they know about sourcing biological drugs and highlight common concerns about safety and supply. Explain that today they will explore how recombinant DNA technology overcomes these challenges, and outline the success criteria: identify three key advantages and compare three recombinant therapeutics.

1. Do‑Now (5') – KWL activity on biological medicines; students list known sources and concerns.
2. Mini‑lecture (10') – Overview of recombinant protein technology and why it matters; show production diagram.
3. Guided analysis (12') – In pairs, examine the comparative table of insulin, factor VIII, and ADA; complete worksheet highlighting each advantage.
4. Whole‑class discussion (8') – Groups share findings; teacher clarifies misconceptions.
5. Case‑study application (10') – Present short patient scenarios for each protein; students argue why the recombinant form is preferred.
6. Formative check (5') – Clicker quiz on key advantages.

Recap that recombinant proteins provide identical sequences, unlimited supply, and enhanced safety, illustrated by insulin, factor VIII, and ADA. Students write one takeaway on an exit ticket. For homework, they research another recombinant therapeutic and note its production system.